Comparison of the diagnostic value of CEA combined with OPN or DKK1 in non‑small cell lung cancer

Abstract

Carcinoma embryonic antigen (CEA), osteopontin (OPN), and Dickkopf-1 (DKK1) expressed in serum are associated with hypoxia in tumor progression. However, the role of these proteins in the plasma of patients with non-small cell lung cancer (NSCLC) is poorly understood. The diagnostic values of CEA combined with OPN or DKK1 were compared in non-small cell lung cancer. This study investigated the diagnostic value of CEA combined with OPN and DKK1, respectively, in NSCLC. Eighty patients with NSCLC (NSCLC group) and 60 patients with benign lung diseases (benign lung disease group) admitted to Shandong Provincial Third Hospital from May 2014 to January 2015 were selected as the study subjects. In addition, 60 healthy subjects undergoing normal physical examination were selected as healthy control group. The OPN and DKK1 in serum of the two groups were detected by enzyme linked immunosorbent assay (ELISA), and the CEA expression was measured by Electrochemical Photometric method. The diagnostic value of CEA combined with OPN and DKK1, respectively, in NSCLC was analyzed. The expression of CEA, OPN, and DKK1 in serum of NSCLC group was significantly higher than that of healthy control group and benign lung disease group (P<0.05). The expression of CEA, OPN and DKK1 in serum of NSCLC patients was correlated with tumor diameter, lymph node metastasis, degree of pathological differentiation and clinical stage (P<0.05). ROC curve for diagnosis of NSCLC was drawn by further combination of serum CEA and OPN. The AUC of combined diagnosis of CEA and OPN for NSCLC was 0.920 (95% CI, 0.875-0.964), and the diagnostic sensitivity and specificity were 87.50 and 86.67%, respectively; the AUC of combined diagnosis of CEA and DKK1 for NSCLC was 0.912 (95% CI, 0.866-0.958), and the diagnostic sensitivity and specificity were 92.50 and 76.67%, respectively. CEA, OPN and DKK1 may be involved in the occurrence and progression of NSCLC and have good sensitivity and specificity in the diagnosis of NSCLC and may be new biomarkers for the diagnosis of NSCLC.

Brain Metastases in Lung Cancer Patients: Clinical Potential Risk Factors of CYFRA21-1 and CEA

“…In addition, high levels of CEA in the serum are linked to higher TNM stages. A number of studies have found that the preoperative level of CEA is an important independent factor related to the survival of patients with nonsmall cell lung cancer [4,5]. Consistent with previous ndings, the results of this study showed that the level of CEA in the serum was positively correlated with brain metastasis, and was an independent factor of lung cancer brain metastasis.…”

Prognosis value of IL-6, IL-8, and IL-1β in serum of patients with lung cancer: A fresh look at interleukins as a biomarker

“…At present, tumor markers have been widely used in the early diagnosis, treatment monitoring, and prognostic evaluation of tumors [ 27 , 28 ]. CEA is a nonspecific tumor-associated antigen that is expressed in many types of tumor, but lacks specificity [ 29 , 30 ].…”

The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer

“…As CEA is usually produced during fetal development, this stops before birth and CEA is usually not present in the blood of healthy adults. At present, CEA is more commonly applied to the diagnosis of adenocarcinoma in non-small cell lung cancer, but its cut-off level varies greatly in different studies ( 14 , 15 ). In one Chinese study, the serum CEA level of non-small cell lung cancer cases was found to be significantly higher than that of benign lung tumor cases and healthy people ( 16 ), while in another, the level in a lung adenocarcinoma group was significantly higher than that of a lung SCC group and small cell lung cancer group ( 17 ).…”